HUP9901016A2 - 4-Kinolinkarboxamid-származékok, előállításuk, valamint neurokinin-3 (NK-3) és neurokinin-2 (NK-2) receptor antagonistákként történő felhasználásuk - Google Patents
4-Kinolinkarboxamid-származékok, előállításuk, valamint neurokinin-3 (NK-3) és neurokinin-2 (NK-2) receptor antagonistákként történő felhasználásukInfo
- Publication number
- HUP9901016A2 HUP9901016A2 HU9901016A HUP9901016A HUP9901016A2 HU P9901016 A2 HUP9901016 A2 HU P9901016A2 HU 9901016 A HU9901016 A HU 9901016A HU P9901016 A HUP9901016 A HU P9901016A HU P9901016 A2 HUP9901016 A2 HU P9901016A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- amino
- carbonyl
- cyclic
- optionally substituted
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 title 1
- 102100024304 Protachykinin-1 Human genes 0.000 title 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- -1 carboxy- Chemical class 0.000 abstract 4
- 239000000843 powder Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- GZAINRLYQOVLRP-UHFFFAOYSA-N 2-[cyano(nitro)amino]-2-oxoacetic acid Chemical compound [N+](=O)([O-])N(C(=O)C(=O)O)C#N GZAINRLYQOVLRP-UHFFFAOYSA-N 0.000 abstract 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 abstract 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 abstract 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 abstract 1
- 102100037342 Substance-K receptor Human genes 0.000 abstract 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000005265 dialkylamine group Chemical group 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003431 oxalo group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány egy (I) általánős képletű vegyületre - amelynek képletében Ar adőtt esetben szűbsztitűált aril-, ciklőalkadienil- vagy adőttesetben szűbsztitűált, mőnőciklűsős vagy kőndenzált gyűrűs, arőmásheterőciklűsős csőpőrt; R alkil-, ciklőalkil-, ciklőalkil-alkil-, adőtt esetben szűbsztitűáltfenil- vagy fenil-(1-6 szénatőmős alkil)-, adőtt esetben szűbsztitűáltöttagú, legfeljebb négy, az őxigén- és/vagy nitrőgénatőm közülkiválasztőtt heterőatőmőt tartalmazó heterőarőmás csőpőrt, hidrőxi-alkil-, aminő-alkil-, alkil-aminő-alkil-, dialkil-aminő-alkil-, acil-aminő-alkil-, alkőxi-alkil-, alkil-karbőnil-, karbőxi-, alkőxi-karbőnil-, alkőxi-karbőnil-alkil-, karbamőil-alkil-aminő-karbőnil-,dialkil-aminő-karbőnil-, halőgén-alkil-, vagy egy, az Ar csőpőrt egyikszénatőmjával gyűrűt képező -(CH2)p- általánős képletű csőpőrt,amelyben p 2 vagy 3; R1 hidrőgénatőm vagy adőtt esetben legfeljebb négy szűbsztitűens akövetkezők közül: alkil-, alkenil-, aril-, alkőxi-, hidrőxicsőpőrt,halőgénatőm, nitrő-, cianő-, karbőxi-, karbőxamidő-, szűlfőnamidő-,alkőxi-karbőnil-, triflűőrmetil-, acil-őxi, ftálimidő-, aminő-, mőnő-vagy dialkil-aminő-csőpőrt; R2 hidrőgénatőm, alkil-, hidrőxi-, halőgénatőm, cianő-, aminő-, mőnő-vagy dialkil-aminő-, alki-szűlfőnil-aminő-, mőnő- vagy dialkanőil-aminő-, ahől bármely alkilcsőpőrt adőtt esetben aminő- vagy dialkil-aminő-csőpőrttal szűbsztitűált, vagy -X-(CH2)n-Y általánős képletűcsőpőrt; R3 alkil-, ciklőalkil-, ciklőalkil-alkil-, adőtt esetben szűbsztitűáltaril- vagy mőnőciklűsős, vagy kőndenzált gyűrűs, arőmás heterőciklűsőscsőpőrt; és R4 hidrőgénatőm vagy alkilcsőpőrt - vagy a vegyületnek egyszőlvátjára, vagy sójára vőnatkőzik. A találmány szerinti vegyületekNK-3 és NK-2 receptőr antagőnisták. ŕ
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI952462 IT1276171B1 (it) | 1995-11-24 | 1995-11-24 | Derivati chinolinici |
| IT96MI001688 IT1307330B1 (it) | 1996-08-02 | 1996-08-02 | Derivati chinolinici |
| PCT/EP1996/005207 WO1997019926A1 (en) | 1995-11-24 | 1996-11-22 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9901016A2 true HUP9901016A2 (hu) | 2000-03-28 |
| HUP9901016A3 HUP9901016A3 (en) | 2002-01-28 |
Family
ID=26331327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9901016A HUP9901016A3 (en) | 1995-11-24 | 1996-11-22 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3(nk-3)-and neurokinin 2(nk-2) receptor antagonists |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20020068827A1 (hu) |
| EP (1) | EP1019377A1 (hu) |
| JP (1) | JP2000513325A (hu) |
| KR (1) | KR19990071598A (hu) |
| CN (1) | CN1207729A (hu) |
| AP (1) | AP9801238A0 (hu) |
| AR (1) | AR004735A1 (hu) |
| AU (1) | AU1031897A (hu) |
| BG (1) | BG102557A (hu) |
| BR (1) | BR9611757A (hu) |
| CA (1) | CA2238328A1 (hu) |
| CZ (1) | CZ158098A3 (hu) |
| DZ (1) | DZ2128A1 (hu) |
| EA (1) | EA001771B1 (hu) |
| HU (1) | HUP9901016A3 (hu) |
| IL (1) | IL124418A0 (hu) |
| MA (1) | MA24011A1 (hu) |
| MX (1) | MX9804108A (hu) |
| NO (1) | NO311213B1 (hu) |
| OA (1) | OA11011A (hu) |
| PL (1) | PL326928A1 (hu) |
| SK (1) | SK66898A3 (hu) |
| TR (1) | TR199800883T2 (hu) |
| TW (1) | TW409123B (hu) |
| UY (2) | UY24375A1 (hu) |
| WO (1) | WO1997019926A1 (hu) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1491533A3 (en) * | 1997-03-14 | 2005-01-19 | Cephalon, Inc. | Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors |
| CA2291111A1 (en) * | 1997-05-23 | 1998-11-26 | Giuseppe Arnaldo Maria Giardina | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| US6262070B1 (en) | 1998-11-04 | 2001-07-17 | Darwin Discovery Ltd. | Heterocyclic compounds and their therapeutic use |
| GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
| US6780875B2 (en) * | 1998-11-20 | 2004-08-24 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| TR200101412T2 (tr) * | 1998-11-20 | 2001-10-22 | Smithkline Beecham S.P.A. | Yeni bileşikler. |
| SE1035115T5 (sv) * | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
| ATE245156T1 (de) * | 1999-03-11 | 2003-08-15 | Neurogen Corp | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden |
| US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| AU4038000A (en) | 1999-03-29 | 2000-10-16 | Neurogen Corporation | 4-substituted quinoline derivatives as gaba receptor ligands |
| AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| WO2002013825A1 (en) * | 2000-08-11 | 2002-02-21 | Smithkline Beecham P.L.C. | Novel pharmaceutical use of quinnoline derivatives |
| WO2002038547A1 (en) * | 2000-11-13 | 2002-05-16 | Glaxosmithkline Spa | Quinoline derivatives as nk-3 and nk-2 antagonists |
| GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
| US6540733B2 (en) | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
| EP1385839B1 (en) * | 2001-04-11 | 2006-02-22 | GlaxoSmithKline S.p.A. | 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| GB0109122D0 (en) * | 2001-04-11 | 2001-05-30 | Smithkline Beecham Spa | Novel compounds |
| MY134211A (en) * | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
| AU2003244080A1 (en) * | 2002-06-26 | 2004-01-19 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| EP1635834A4 (en) * | 2003-06-25 | 2009-12-02 | Smithkline Beecham Corp | NEW COMPOUNDS |
| US7288658B2 (en) | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| GB0318727D0 (en) * | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0425077D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
| MX2007014831A (es) * | 2005-06-03 | 2008-02-15 | Astrazeneca Ab | Derivados de quinolina como antagonistas de neurocinina-3. |
| US20080194622A1 (en) * | 2005-06-23 | 2008-08-14 | Astrazeneca Ab | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators |
| GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2007018469A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Oxopyridyl quinoline amides as nk3 receptor modulators |
| EP1915362A1 (en) * | 2005-08-11 | 2008-04-30 | AstraZeneca AB | Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
| US20080287492A1 (en) * | 2005-08-11 | 2008-11-20 | Astrazeneca Ab | Alkylpyridyl Quinolines as Nk3 Receptor Modulators |
| AR058051A1 (es) * | 2005-09-21 | 2008-01-23 | Astrazeneca Ab | Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas. |
| AR057130A1 (es) | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
| TW201018662A (en) * | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| JP2010522227A (ja) | 2007-03-22 | 2010-07-01 | アストラゼネカ・アクチエボラーグ | 炎症性疾患の処置のためのキノリン誘導体 |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| CN102924375B (zh) * | 2012-06-21 | 2015-02-18 | 江苏恩华药业股份有限公司 | Talnetant中间体及其制备方法和应用 |
| CA2909752A1 (en) | 2013-04-19 | 2014-10-23 | Astrazeneca Ab | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| US10117864B2 (en) | 2015-03-18 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof |
| WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
| WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
| WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
| TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| JP7107963B2 (ja) | 2017-04-10 | 2022-07-27 | バイエル・アクチエンゲゼルシヤフト | 置換されたｎ－アリールエチル－２－アリールキノリン－４－カルボキサミド類及びそれの使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2538388B1 (fr) * | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US5482967A (en) * | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
| KR100316571B1 (ko) * | 1994-05-27 | 2002-05-30 | 파올로 비지, 엔리꼬 카쭐라니 | 타키키닌nk3수용체길항제로서퀴놀린유도체 |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1996
- 1996-11-21 AR ARP960105282A patent/AR004735A1/es unknown
- 1996-11-22 IL IL12441896A patent/IL124418A0/xx unknown
- 1996-11-22 PL PL96326928A patent/PL326928A1/xx unknown
- 1996-11-22 CN CN96199747A patent/CN1207729A/zh active Pending
- 1996-11-22 AU AU10318/97A patent/AU1031897A/en not_active Abandoned
- 1996-11-22 JP JP09520158A patent/JP2000513325A/ja active Pending
- 1996-11-22 TR TR1998/00883T patent/TR199800883T2/xx unknown
- 1996-11-22 KR KR1019980703874A patent/KR19990071598A/ko not_active Application Discontinuation
- 1996-11-22 MA MA24399A patent/MA24011A1/fr unknown
- 1996-11-22 CZ CZ981580A patent/CZ158098A3/cs unknown
- 1996-11-22 EP EP96941025A patent/EP1019377A1/en not_active Withdrawn
- 1996-11-22 HU HU9901016A patent/HUP9901016A3/hu unknown
- 1996-11-22 BR BR9611757A patent/BR9611757A/pt unknown
- 1996-11-22 UY UY24375A patent/UY24375A1/es not_active IP Right Cessation
- 1996-11-22 WO PCT/EP1996/005207 patent/WO1997019926A1/en not_active Application Discontinuation
- 1996-11-22 SK SK668-98A patent/SK66898A3/sk unknown
- 1996-11-22 AP APAP/P/1998/001238A patent/AP9801238A0/en unknown
- 1996-11-22 EA EA199800538A patent/EA001771B1/ru not_active IP Right Cessation
- 1996-11-22 CA CA002238328A patent/CA2238328A1/en not_active Abandoned
- 1996-11-23 DZ DZ960173A patent/DZ2128A1/fr active
- 1996-11-23 TW TW085114501A patent/TW409123B/zh not_active IP Right Cessation
-
1997
- 1997-05-16 UY UY24555A patent/UY24555A1/es not_active Application Discontinuation
-
1998
- 1998-05-22 OA OA9800062A patent/OA11011A/en unknown
- 1998-05-22 MX MX9804108A patent/MX9804108A/es unknown
- 1998-05-22 NO NO19982333A patent/NO311213B1/no not_active IP Right Cessation
- 1998-06-18 BG BG102557A patent/BG102557A/bg unknown
-
2001
- 2001-11-26 US US09/994,402 patent/US20020068827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA001771B1 (ru) | 2001-08-27 |
| IL124418A0 (en) | 1998-12-06 |
| NO311213B1 (no) | 2001-10-29 |
| US20020068827A1 (en) | 2002-06-06 |
| EP1019377A1 (en) | 2000-07-19 |
| OA11011A (en) | 2003-03-06 |
| AU1031897A (en) | 1997-06-19 |
| BR9611757A (pt) | 1999-04-06 |
| HUP9901016A3 (en) | 2002-01-28 |
| JP2000513325A (ja) | 2000-10-10 |
| NO982333L (no) | 1998-07-22 |
| AP9801238A0 (en) | 1998-06-30 |
| UY24375A1 (es) | 1997-05-22 |
| BG102557A (bg) | 1999-03-31 |
| UY24555A1 (es) | 2001-04-30 |
| MX9804108A (es) | 1998-09-30 |
| SK66898A3 (en) | 1998-12-02 |
| TR199800883T2 (xx) | 2000-12-21 |
| EA199800538A1 (ru) | 1998-12-24 |
| CZ158098A3 (cs) | 1998-10-14 |
| MA24011A1 (fr) | 1997-07-01 |
| WO1997019926A1 (en) | 1997-06-05 |
| AR004735A1 (es) | 1999-03-10 |
| KR19990071598A (ko) | 1999-09-27 |
| TW409123B (en) | 2000-10-21 |
| CN1207729A (zh) | 1999-02-10 |
| CA2238328A1 (en) | 1997-06-05 |
| DZ2128A1 (fr) | 2002-10-26 |
| NO982333D0 (no) | 1998-05-22 |
| PL326928A1 (en) | 1998-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9901016A2 (hu) | 4-Kinolinkarboxamid-származékok, előállításuk, valamint neurokinin-3 (NK-3) és neurokinin-2 (NK-2) receptor antagonistákként történő felhasználásuk | |
| MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| TR200003598T2 (tr) | Amid türevleri ve nosiseptin antagonistleri | |
| HUP0302337A2 (hu) | Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203973A2 (hu) | Szulfonamid-tartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0001243A2 (hu) | Nikotinamidszármazékok és a vegyületeket tartalmazó gyógyszerészeti készítmények | |
| HUP0001123A2 (hu) | Kombinált 5HT1A, 5HT1B és 5HT1D receptor antagonista aktivitással rendelkező indolszármazékok | |
| HUP9902459A2 (hu) | Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására | |
| CY1105688T1 (el) | Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης | |
| HUP0301573A2 (hu) | Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HU9501622D0 (en) | 1,4-benzodiazepine derivatives and their use as cck-mudulators | |
| ATE156804T1 (de) | Ethanolamin-derivate mit sympathomimetischer und anti-pollakiuria wirkung | |
| HUP0203645A2 (hu) | Fenilpiperazinil-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP9801838A2 (hu) | Specifikus ingerlő aminosav antagonista indolszármazékok | |
| HUP0002300A2 (hu) | 4-Kinolinkarboxamid-származékok, előállításuk, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| ATE182889T1 (de) | Bicyclische amidinderivate als no-synthetase inhibitoren | |
| HUP9900040A2 (hu) | NMDA antagonista hatású tetrahidrokinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP9801386A2 (hu) | Szerotonin 5-HT4 receptor parciális agonistáiként és antagonistáiként alkalmazható indazol-karboxamid-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0203603A2 (hu) | Új IL-8 receptor antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE453621T1 (de) | Substituierte 4-phenylpiperidinamide als tachykininantagonisten und serotoninwiederaufnahmehemmer | |
| HUP9701325A1 (hu) | Új 2,3-benzodiazepin-származékok | |
| HUP9603498A2 (hu) | Indolszármazékok és e vegyületeket tartalmazó gyógyászati készítmények | |
| BG106079A (en) | Cyclocarbamate derivatives as progesterone receptor modulators | |
| NO980144D0 (no) | Nye heterocykliske forbindelser for behandling av smerte og anvendelse derav | |
| CY1105509T1 (el) | Παραγωγα ινδολιου που διαθετουν ανταγωνιστικες ιδιοτητες των 5ητ2c, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν |